Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 May;21(3):e176-e183.
doi: 10.1016/j.jcf.2022.02.012. Epub 2022 Feb 21.

The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

Joseph L Simonson  1 , Christine Esposito  2 , Theresa Frantzen  3 , Katherine Henthorne  4 , Aileen Espinal  5 , Serena Romano  6 , Ramona Ramdeo  7 , Jessica Trentacoste  8 , Donna Tsang  9 , Geralyn LaVecchia  10 , Robert Abdullah  11 , Maria Berdella  12 , Lynn Bonitz  13 , Rany Condos  14 , Andrei Constantinescu  15 , Joan K DeCelie-Germana  16 , Emily DiMango  17 , Myah Draine  18 , Tara Gimeli  19 , Robert Giusti  20 , Jessenia Guzman  21 , Soumia Hammouda  22 , Claire Keating  23 , Catherine Kier  24 , Alison T Lennox  25 , Carmen Liriano  26 , Zachary Messer  27 , Amy Plachta  28 , Hossein Sadeghi  29 , Elinor Schwind  30 , Teresa Stables-Carney  31 , Patricia Walker  32 , Janice Wang  33
Affiliations
Multicenter Study

The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

Joseph L Simonson et al. J Cyst Fibros. 2022 May.

Abstract

Background: People with cystic fibrosis (pwCF) may be at risk of complications from COVID-19 but the impact of COVID-19 on pwCF remains unknown.

Methods: We conducted a multicenter retrospective cohort study to assess the impact of the COVID-19 pandemic first wave on pwCF in the New York metropolitan area (NY) from March 1, 2020 to August 31, 2020. Objectives were to determine (1) the prevalence of COVID-19 by PCR and IgG antibody testing, (2) the clinical characteristics of COVID-19, (3) delay in routine outpatient care, and (4) the effect on anxiety and depression in pwCF.

Results: There were 26 COVID-19 cases diagnosed by PCR or antibody testing among the study cohort of 810 pwCF. The prevalence of COVID-19 by PCR (1.6%) and IgG antibody (12.2%) testing was low. 58% of cases were asymptomatic and 82% were managed at home. 8% were hospitalized and 1 person died. 89% of pwCF experienced delay in care. The prevalence of anxiety increased from 43% baseline to 58% during the pandemic (P<0.01). In post-hoc analysis, the proportion of patients with diabetes (38% versus 16%, P<0.01) and pancreatic insufficiency (96% versus 66%, P<0.01) were higher while CFTR modulator use was lower (46% versus 65%, P = 0.05) in pwCF who tested positive for COVID-19.

Conclusions: The prevalence of COVID-19 among pwCF in NY during the pandemic first wave was low and most cases were managed at home. CFTR modulators may be protective. PwCF experienced delay in routine care and increased anxiety.

Keywords: Coronavirus; Covid-19; Cystic fibrosis; SARS-CoV2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no conflicts of interest.

Figures

Fig. 1:
Fig. 1
Prevalence of COVID-19 infection in patients with cystic fibrosis.
Fig. 2:
Fig. 2
Delay in routine outpatient care for patients with cystic fibrosis from March 1, 2020 to May 31, 2020.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/. Accessed June 6, 2021.
    1. Ko J.Y., Danielson M.L., Town M., Derado G., Greenlund K.J., Kirley P.D., et al. Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis. 2021;72(11):e695–e703. doi: 10.1093/cid/ciaa1419. - DOI - PMC - PubMed
    1. Wiltshire D.A., Vahora I.S., Tsouklidis N., Kumar R., Khan S. H1N1 influenza virus in patients with cystic fibrosis: a literature review examining both disease entities and their association in light of the 2009 pandemic. Cureus. 2020;12(7):e9218. doi: 10.7759/cureus.9218. - DOI - PMC - PubMed
    1. Renk H., Regamey N., Hartl D. Influenza A(H1N1)pdm09 and cystic fibrosis lung disease: a systematic meta-analysis. PLoS One. 2014;9(1):e78583. doi: 10.1371/journal.pone.0078583. - DOI - PMC - PubMed
    1. Cosgriff R., Ahern S., Bell S.C., Keith B., Pierre-Regis B., Byrnes C., et al. A multinational report to characterized SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros. 2020;19(3):355–358. doi: 10.1016/j.jcf.2020.04.012. - DOI - PMC - PubMed

Publication types

Substances